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Ex vivo gene transfer in the years to come
Abstract
Synovial fibroblasts (SFs) have become a major target for ex vivo gene transfer in rheumatoid arthritis
(RA), but efficient transduction of RA-SFs still is a major problem. The low proliferation rate and
heterogeneity of RA-SFs, together with their lack of highly specific surface receptors, have hampered a
more extensive application of this technique. Improving transduction protocols with conventional viral
vectors, therefore, as well as developing novel strategies, such as alternative target cells, and novel
delivery systems constitute a major challenge. Recent progress in this field will lead to the achievement
of high transgene expression, and will facilitate the use of gene transfer in human trials.
CIA = collagen-induced arthritis; Fv = variable fragment (of an antibody); IL = interleukin; IL-1Ra = interleukin-1 receptor antagonist; RA = rheuma-
toid arthritis; SF = synovial fibroblast; TCR = T-cell receptor.
Available online http://arthritis-research.com/content/4/1/010
Introduction
It is now well established that successful approaches to
gene transfer in rheumatoid arthritis (RA) require three
main questions to be answered. What genes or gene con-
structs should be used? Which cells should be targeted?
How should the transgenes be delivered to the respective
target cells [1]? These questions appear to be distinct,
but in fact are linked closely to one another. Gene transfer
designed to alter signalling pathways or the expression of
matrix degrading enzymes will thus require in vivo
approaches that ensure transduction of the majority of the
synovial (lining) cells [2]. In contrast, gene transfer of
secreted proteins can be done successfully, also ex vivo,
where only a limited number of synovial cells is transduced
[3]. Provided the expression levels of the soluble factors
are high enough, re-injection of the transduced cells into
the joint will give significant effects. In theory, these effects
are limited only by the life span of the cell or may even
exceed it when constructs are used that result in integra-
tion into the genome.
Ex vivo gene transfer of cytokines or (soluble) cytokine
receptors/antagonists to synovial fibroblasts (SFs) has
been suggested as a promising approach to interfere with
synovial inflammation [4]. This is based both on the under-
standing that inflammatory cytokines contribute signifi-
cantly to the pathogenesis of disease [5–8] and on our
growing awareness of SFs as one major cell type involved
in the destructive process of RA [9,10]. Fibroblast-like
cells make up the largest population of resident cells in
the synovium and can be grown easily in vitro. When their
cellular properties are considered, however, RA-SFs are
far from being ideal for gene transfer. They lack the
expression of highly specific surface markers and their
proliferation rate is relatively low. Also, RA-SFs are not a
homogeneous population of cells, but several lines of
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evidence suggest that there are at least two subtypes of
RA-SF that differ in their morphological and molecular
characteristics. Growing and passaging these cells may,
therefore, result in the selection of certain subtypes that,
so far, have been hardly characterized. On the other hand,
early passage RA-SFs, such as those obtained from the
enzymatic digestion of synovial tissues, will contain a
certain percentage of tissue macrophages that have dis-
tinct characteristics with respect to their transduction with
viral vectors.
Use of retroviral delivery systems with RA-SFs
For ex vivo gene transfer of RA-SFs, retroviral vectors
have been used frequently. This is because retroviruses
are easy to produce and, through integration of their
genetic information into the host genome, they can
achieve long-lasting expression of the transgene. Apart
from the duration of expression, however, actual levels of
transgene expression are critical for successful gene
therapy approaches. These are determined by the pro-
moter that is used for transgene expression and the actual
transduction efficacy (i.e. the percentage of cells that can
be transduced from a certain population). Retroviruses
can transduce only dividing cells, which limits their use
with RA-SFs. For in vitro experiments or animal studies,
several retroviral vectors have been developed that
contain antibiotic resistance genes and allow for the
selection of successfully transduced cells. Such vectors,
however, cannot be used for human trials.
Several techniques [11] have been developed that allow
the enhancement of the efficacy of retroviral transduction:
the extension of the time of transduction and repeated
transductions [12]; the use of different cationic agents
[13]; centrifugation [14]; and flow-through techniques
[15]. While these techniques are not new per se, little is
known about their application in the retroviral transduction
of human RA-SFs. In this context, del Vechio and col-
leagues recently reported their experience in using differ-
ent strategies to optimise the transduction efficacy of
RA-SFs [16]. They demonstrated that the application of a
combination of methods may enhance significantly the
production of the interleukin-1 receptor antagonist
(IL-1Ra) in RA-SFs that were infected with an MFG
vector-based retroviral construct carrying the IL-1Ra gene.
This is of interest, because their experience is taken
directly from the first human clinical trial of arthritis gene
therapy approved by the Recombinant DNA Advisory
Committee of the National Institutes of Health in the
United States and the US Food and Drug Administration
[17]. Consequently, the paper raises a number of issues
that are of importance, not only for the reported human
trial but also for future clinical studies using gene transfer
in RA. They demonstrated that virus titers of about 108
infectious particles per millilitre, together with the use of
the lipopolyamine, dioctadecylamidoglycylspermine, instead
of the conventional Polybrene, significantly enhance the
levels of IL-1Ra produced by transduced RA-SFs. Cen-
trifugation of the cells during transduction or flow-through
resulted in a further dramatic effect; the highest levels
were nearly 1 µg of IL-1Ra per 106 cells. This is of impor-
tance because inhibition of IL-1 by IL-1Ra requires a large
molar excess that is difficult to achieve by pharmacological
approaches. In the report, the exact number of success-
fully transduced cells was not investigated, but the
increase in the production of IL-1Ra is probably due to an
increase in transduction efficacy. Although the authors do
not show the data of all combinations and give no specific
recommendation as to which combination of techniques
should be used, it may be speculated that the use of high
viral titers, in combination with dioctadecylamidogly-
cylspermine and centrifugation/flow-through techniques,
may result in the best transduction efficacy and, thus, in
highest levels of proteins.
Further studies will be needed to see whether the
described levels of IL-1Ra production can be maintained
over time. It has been reported [8,18,19], that the severe
combined immunodeficient mouse co-implantation model of
RA may serve as a useful tool to investigate the long-term
effects of modified transduction protocols on the expression
and biological consequences of gene transfer. In this model,
the question of whether cryoconservation affects the trans-
duction of RA-SFs could also be answered.
Alternative ex vivo approaches for RA
Despite the advances in improving retroviral transduction
of RA-SFs, several alternative strategies are being devel-
oped that permit efficient ex vivo gene transfer of
secreted, anti-inflammatory molecules. As discussed at
the Second International Meeting on Gene and Cell Ther-
apies of Arthritis and Related Disorders in Montpellier
[20], the efficacy of ex vivo approaches may be increased
when cell types other than RA-SFs are used. Such cells
may not be specific for the rheumatoid synovium but, fol-
lowing genetic modification, accumulate in the RA joint
and secrete anti-inflammatory molecules.
Several groups have proposed to use genetically engi-
neered T cells that would home specifically into arthritic
joints and deliver anti-inflammatory molecules to the site of
inflammation. Nakajima and colleagues thus used type II-
collagen-specific CD4+ T cells that were transduced with
retroviruses to express green fluorescent protein and they
demonstrated that these cells accumulated and remained
in the inflamed joints of collagen-induced arthritis (CIA)
[21]. Using this method to deliver IL-12 after primary
immunization, the authors found significant inhibition in the
development of CIA. Chernajovsky and co-workers used
retroviral delivery to engineer mouse T cells expressing a
chimeric receptor that included the single chain Fv domain
of the anti-type-II-collagen monoclonal antibody, C2, the
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hinge region of CD8-α and the transmembrane and cyto-
plasmic domains of TCR-ζ [22]. As suggested, such T
cells can be used as gene carriers in arthritis.
Other approaches include the use of mesenchymal stem
cells, dendritic cells or muscle cells rather than RA-SFs. It
has been demonstrated that myoblasts can be transduced
more efficiently than synovial cells, and that after intra-
articular injection they adhere to different structures in the
joint [23]. Recently, dendritic cells (derived from bone
marrow), transduced with retroviral vectors carrying the
IL-4 gene, were applied successfully to reduce the inci-
dence of CIA in mice, as well as to suppress established
disease in these animals [24]. In this approach, however,
the effects were attributed to the migration of the geneti-
cally engineered dendritic cells to lymphoid organs and
subsequent modulation of the T cell repertoire, rather that
to an intra-articular expression of the transgene.
Apart from the use of alternative target cells, novel viral
vectors are under development that may also be used for
efficient ex vivo gene transfer. These include vectors
derived from adeno-associated viruses as well as lentiviral
vectors.
Conclusions
Despite a continuous increase of efforts to establish in
vivo protocols for gene transfer of arthritis, ex vivo gene
transfer of secreted factors such as cytokines or cytokine
receptors/antagonists bear a great potential, and are the
most advanced when it comes to possible clinical applica-
tions. Further modifications of protocols will help to
increase the transduction efficacy and facilitate the estab-
lishment of clinical trials that are based on known vector
systems. In addition, the use of alternative target cells will
take advantage of the complexity of disease and may
result in a site-specific delivery of ex vivo transduced but
systemically applied cells.
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